Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY-2940094 in stress-induced depression/anxiety phenotypes
NCT06786637Phase 2Withdrawn
- Sponsor
- McLean Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of LY2940094 in major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by McLean Hospital. Primary endpoints: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Childhood Trauma Questionnaire and 6 more. Planned start Jun 2025; status: withdrawn.
02
Drugs
LY2940094
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT06786637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786637.